CORPORATE ACCESS

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of...

Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour SegalPETACH TIKVA, Israel, Nov. 07, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to...

PETACH TIKVA, Israel, Nov. 01, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights...

PETACH TIKVA, Israel, Oct. 11, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that...

PETACH TIKVA, Israel, Oct. 09, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation...

Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. 04, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...

PETACH TIKVA, Israel, Sept. 22, 2023 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company's management will present at the Cantor Global Healthcare Conference...

Successful Audit of the Company's State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX GloballyPETACH TIKVA, Israel, Sept. 21, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...

PETACH TIKVA, Israel, Sept. 20, 2023 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the "Reverse Split") of the Company's issued and outstanding...

Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX100 NDA and MAA Regulatory Filings PETACH TIKVA, Israel, Sept. 19, 2023 -- PolyPid Ltd....